Cargando…

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice

Spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality. The advent of approved treatments for this devastating condition has significantly changed SMA patients' life expectancy and quality of life. Nevertheless, these are not without limitations, and research efforts are u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kordala, Anna J, Stoodley, Jessica, Ahlskog, Nina, Hanifi, Muhammad, Garcia Guerra, Antonio, Bhomra, Amarjit, Lim, Wooi Fang, Murray, Lyndsay M, Talbot, Kevin, Hammond, Suzan M, Wood, Matthew JA, Rinaldi, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630883/ https://www.ncbi.nlm.nih.gov/pubmed/37724723 http://dx.doi.org/10.15252/emmm.202317683

Ejemplares similares

The Carrier Frequency of Two SMN1 Genes in Parents of Symptomatic Children with SMA and the Significance of SMN1 Exon 8 in Carriers
por: Davidson, Joanne E, et al.
Publicado: (2023)

Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021)

Subtle mutations in the SMN1 gene in Chinese patients with SMA: p.Arg288Met mutation causing SMN1 transcript exclusion of exon7
por: Yu-jin, Qu, et al.
Publicado: (2012)

Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Functional characterization of SMN evolution in mouse models of SMA
por: Osman, Erkan Y., et al.
Publicado: (2019)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

NFL is a marker of treatment response in children with SMA treated with nusinersen
por: Olsson, Bob, et al.
Publicado: (2019)

Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
por: Wang, Yiran, et al.
Publicado: (2019)

SMA-linked SMN mutants prevent phase separation properties and SMN interactions with FMRP family members
por: Binda, Olivier, et al.
Publicado: (2022)

Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model
por: Hua, Yimin, et al.
Publicado: (2011)

How do SMA-linked mutations of SMN1 lead to structural/functional deficiency of the SMA protein?
por: Li, Wei
Publicado: (2017)

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
por: Wurster, Claudia D., et al.
Publicado: (2019)

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
por: Vidovic, Maximilian, et al.
Publicado: (2023)

High Expression Level of Tra2-β1 Is Responsible for Increased SMN2 Exon 7 Inclusion in the Testis of SMA Mice
por: Chen, Yu-Chia, et al.
Publicado: (2015)

Pathological impact of SMN2 mis-splicing in adult SMA mice
por: Sahashi, Kentaro, et al.
Publicado: (2013)

Possible implication of undescribed SMN1-SMN2 genotype in chronic EMG-pattern of SMA with transitory acute denervation
por: Vitello, Girolamo A., et al.
Publicado: (2020)

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients
por: Bonanno, Silvia, et al.
Publicado: (2020)

Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study
por: Gallone, Annamaria, et al.
Publicado: (2022)

Correction: Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
por: Vidovic, Maximilian, et al.
Publicado: (2023)

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen
por: Garofalo, M., et al.
Publicado: (2023)

Cervical Spinal Cord Atrophy Profile in Adult SMN1-Linked SMA
por: El Mendili, Mohamed-Mounir, et al.
Publicado: (2016)

A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients
por: Savad, Shahram, et al.
Publicado: (2023)

Alternative splicing of a cryptic exon embedded in intron 6 of SMN1 and SMN2
por: Yoshimoto, Satomi, et al.
Publicado: (2016)

Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-up
por: Barp, Andrea, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Successful weaning from mechanical ventilation in a patient with SMA type 1 treated with nusinersen
por: Lee, Jiwon, et al.
Publicado: (2021)

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients
por: Pane, Marika, et al.
Publicado: (2021)

Effect of the COVID-19 Pandemic on Children With SMA Receiving Nusinersen: What Is Missed and What Is Gained?
por: Agosto, Caterina, et al.
Publicado: (2021)

Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months
por: De Wel, Bram, et al.
Publicado: (2022)

The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
por: Scheijmans, Féline E. V., et al.
Publicado: (2022)

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
por: Hua, Yimin, et al.
Publicado: (2007)

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy
por: Chiriboga, Claudia A., et al.
Publicado: (2016)

A homozygous double mutation in SMN1: a complicated genetic diagnosis of SMA
por: Kirwin, Susan M, et al.
Publicado: (2013)

Correction: Cervical Spinal Cord Atrophy Profile in Adult SMN1-Linked SMA
por: El Mendili, Mohamed-Mounir, et al.
Publicado: (2016)

Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany
por: Pechmann, Astrid, et al.
Publicado: (2018)

Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review
por: Ali, Imran, et al.
Publicado: (2019)

Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen
por: Trifunov, Selena, et al.
Publicado: (2023)

Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene
por: Hao, Le T, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_da9kut1o5ijv0rctqnmvnarbg8